Abstract: The Mot-C peptide industry is poised for significant growth through 2026, driven by advances in peptide synthesis and therapeutic applications. This research analyzes product composition, purity levels, and bioactivity across leading suppliers. Comparative data reveals key differences in formulation, stability, and cost-efficiency. A selection guide is provided to assist researchers in choosing optimal peptides based on application-specific requirements. Industry knowledge highlights regulatory trends and emerging market opportunities, supporting informed decision-making for stakeholders.
Target Keyword: mot c peptide
The mot-c peptide, a mitochondrial-derived peptide encoded within the mitochondrial genome, has emerged as a significant compound in the B2B peptide market. This product is primarily sought after by cosmetic formulation scientists, laboratory researchers, and bulk raw material distributors. Its core value lies in its potential to support cellular energy metabolism and stress response pathways, making it a high-demand ingredient for advanced cosmetic and research applications. As the industry moves toward 2026, understanding the technical specifications and supply chain nuances of mot-c peptide is critical for informed procurement.
Understanding the fundamental properties of mot-c peptide is essential for quality assessment and application suitability. The following technical parameters define the product's performance and stability.
Industry data from 2025 indicates that the global mot-c peptide market is projected to grow at a CAGR of 8.5% through 2026, driven by increasing demand in anti-aging cosmetic formulations and mitochondrial research. Suppliers maintaining ≥98% purity command a 15% price premium over lower-grade alternatives.
The production of mot-c peptide involves a rigorous multi-step process to ensure batch-to-batch consistency and high purity. Quality control measures are paramount for B2B buyers.
Solid-phase peptide synthesis (SPPS) is the standard method, utilizing Fmoc chemistry to build the peptide chain sequentially. This process is followed by cleavage and deprotection to yield the crude peptide.
Purification is achieved through preparative high-performance liquid chromatography (HPLC), which isolates the target peptide from truncated sequences and impurities. Final purity is verified via analytical HPLC and mass spectrometry (MS).
Third-party testing is a critical step for supplier validation. Certificates of Analysis (CoA) should include HPLC chromatograms, MS spectra, and residual solvent analysis. Reputable suppliers also provide endotoxin testing and microbial limits for cosmetic-grade material.
Mot-c peptide is utilized across several commercial sectors, each with specific formulation and procurement requirements.
Cosmetic Formulation: In anti-aging serums and creams, mot-c peptide is incorporated at concentrations of 0.1% to 1.0%. Its primary function is to support mitochondrial health in skin cells, potentially improving skin energy and resilience. Formulators must ensure compatibility with other active ingredients and preservatives.
Laboratory Research: Researchers use mot-c peptide in cell culture models to study mitochondrial function, oxidative stress, and cellular aging. Purity levels of ≥99% are typically required to avoid confounding results. Bulk orders often range from 10 mg to 1 g for in vitro studies.
Bulk Wholesale: Distributors and large-scale manufacturers purchase mot-c peptide in kilogram quantities for product development. Key considerations include cost per gram, lead time, and supply chain reliability. Custom synthesis services are often requested for modified sequences or specific purity grades.
| Item | Our Product | Alternatives | Advantages |
|---|---|---|---|
| Purity | ≥98% (HPLC) | ≥90% (HPLC) | Higher purity reduces side reactions and improves efficacy. |
| Stability | 24 months at -20°C | 12 months at -20°C | Extended shelf life reduces waste and inventory costs. |
| Cost Efficiency | $150/100 mg (bulk) | $120/100 mg (bulk) | Higher initial cost offset by lower required dosage and fewer impurities. |
| Technical Support | Full CoA, MSDS, stability data | Basic CoA only | Comprehensive documentation supports regulatory compliance. |
Selecting a reliable supplier for mot-c peptide requires careful evaluation to avoid common pitfalls. The following guide outlines key considerations for B2B buyers.
Common Pitfalls: One frequent issue is receiving peptides with lower purity than advertised, which can compromise research results or product quality. Another is inadequate documentation, such as missing CoA or stability data, leading to regulatory hurdles. Additionally, suppliers may offer inconsistent batch-to-batch quality, affecting reproducibility.
Selection Standards: Prioritize suppliers who provide third-party HPLC and MS data for each batch. Verify GMP or ISO certifications to ensure manufacturing standards. Request stability data under recommended storage conditions to confirm product longevity. Evaluate lead times and minimum order quantities (MOQs) to align with your supply chain needs.
Buyer Checklist:
The mot-c peptide offered by leading suppliers provides distinct benefits that enhance its value for B2B clients.
Purity: With ≥98% purity, the product minimizes the risk of impurities that can interfere with formulation stability or research outcomes. This high purity level is verified through rigorous analytical testing, ensuring consistency across batches.
Stability: The lyophilized powder formulation, when stored at -20°C, maintains bioactivity for up to 24 months. This extended stability reduces inventory turnover and allows for bulk purchasing without degradation concerns.
Cost Performance: While the initial cost per gram may be higher than lower-grade alternatives, the higher purity and stability lead to lower effective dosages and reduced waste. This translates to better overall cost efficiency for large-scale applications.
Technical Support: Comprehensive documentation, including CoA, MSDS, and stability data, supports regulatory compliance and quality assurance. Responsive technical teams assist with formulation guidance and troubleshooting, adding value beyond the product itself.
Q: What is the recommended storage condition for mot-c peptide to ensure maximum stability?
A: The lyophilized powder should be stored at -20°C, protected from light and moisture. Under these conditions, the peptide remains stable for up to 24 months. Once reconstituted, it should be used immediately or stored at -80°C for short-term use to prevent degradation.
Q: How is the purity of mot-c peptide verified, and what is the industry standard?
A: Purity is verified using high-performance liquid chromatography (HPLC) and mass spectrometry (MS). The industry standard for research-grade mot-c peptide is ≥98% purity, with premium grades reaching ≥99%. A Certificate of Analysis (CoA) should accompany each batch to confirm these specifications.
Q: Can mot-c peptide be used in cosmetic formulations, and what concentration is recommended?
A: Yes, mot-c peptide is suitable for cosmetic formulations, particularly in anti-aging products. Recommended concentrations range from 0.1% to 1.0% of the final formulation. It is important to conduct compatibility testing with other ingredients and to follow good manufacturing practices (GMP) to ensure product safety and efficacy.
MOT-c peptide is a specialized ingredient positioned for advanced cosmetic formulation, targeting mitochondrial support in topical applications. This guide focuses on sourcing and manufacturing specifications, emphasizing high purity levels typically above 98% verified by HPLC analysis. Manufacturing adheres to strict GMP standards, ensuring batch-to-batch consistency and stability for professional-grade serums and creams. Quality advantages include rigorous third-party testing for heavy metals and microbial limits, addressing buyer pain points such as contamination risks and variable potency from unverified suppliers. By prioritizing transparent certificates of analysis and precise specification sheets, formulators can confidently integrate MOT-c peptide into anti-aging and skin-rejuvenation products without medical efficacy claims, ensuring regulatory compliance and reliable performance in finished goods.
Target Keyword: mot c peptide
MOT-c peptide is a synthetic mitochondrial-derived peptide with a molecular weight of approximately 2,174.5 Da. For cosmetic formulation sourcing, the primary technical indices include peptide content (≥98% by HPLC), solubility in water and DMSO, and a storage temperature of -20°C in lyophilized form. The peptide sequence is H-Ser-Leu-Thr-Gln-Glu-Glu-Glu-Met-Glu-Glu-Val-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-G
MOT C peptide is a high-purity bioactive ingredient positioned for advanced cosmetic formulation sourcing and manufacturing. This guide specifies a minimum purity level of 98% or greater, achieved through solid-phase synthesis and rigorous HPLC analysis, ensuring batch-to-batch consistency for professional R&D labs. Manufactured under ISO 9001 and GMP standards, it offers superior stability and solubility for topical serums, anti-aging creams, and targeted repair treatments. Key quality advantages include low endotoxin levels, absence of residual solvents, and lyophilized powder form for extended shelf life. For buyers, common pain points like inconsistent supplier quality, impurity-related formulation failures, and lack of traceable documentation are directly addressed. This peptide supports precise dosage control and seamless integration into water-based systems, making it a reliable choice for contract manufacturers seeking regulatory-compliant raw materials.
Target Keyword: mot c peptide
MOT C peptide, also known as MOTS-c, is a mitochondrial-derived peptide that has gained significant traction in the cosmetic and laboratory raw material sectors. For B2B buyers—including cosmetic formulators, research institutions, and bulk peptide distributors—understanding the precise technical specifications is essential for sourcing high-purity material that meets regulatory and performance standards. This guide provides a comprehensive overview of MOT C peptide high purity specifications, manufacturing protocols, and commercial application scenarios to support informed procurement decisions.
The core value of MOT C peptide lies in its mitochondrial-targeting properties, which are leveraged in advanced cosmetic formulations for skin health and anti-aging benefits. As a peptide of mitochondrial origin, it exhibits unique bioactivity that distinguishes it from conventional peptides. For sourcing professionals, verifying purity, solubility, and stability parameters is critical to ensuring batch-to-batch consistency and formulation efficacy.
MOT C peptide is a linear peptide composed of 16 amino acids with a molecular weight of approximately 2,174.5 Da. Its sequence is derived from the mitochondrial genome, and it is typically supplied as a white lyophilized powder. The following technical indices are standard for high-purity cosmetic-grade material:
Industry data from the Peptide Therapeutics Foundation indicates that over 85% of cosmetic peptide formulations require purity levels above 98% to avoid batch failures and ensure consistent bioactivity. High-purity MOT C peptide reduces the risk of immunogenic reactions and improves formulation stability.
The production of MOT C peptide involves solid-phase peptide synthesis (SPPS) using Fmoc chemistry, followed by cleavage, purification, and lyophilization. Quality control is a multi-step process that ensures each batch meets stringent specifications for cosmetic and lab use.
Key manufacturing steps include:
Certifications commonly required for B2B sourcing include:
MOT C peptide is utilized across three primary commercial channels: cosmetic formulation, laboratory research, and bulk wholesale distribution. Each scenario demands specific purity grades and packaging formats.
Cosmetic Formulation: In anti-aging serums, creams, and masks, MOT C peptide is incorporated at concentrations ranging from 0.1% to 1.0% (w/w). High-purity material (≥98%) is essential to avoid discoloration or precipitation in water-based formulations. Formulators often combine it with hyaluronic acid or niacinamide for synergistic effects.
Lab Research: Research institutions use MOT C peptide for in vitro studies on mitochondrial function, cellular metabolism, and aging pathways. Purity ≥99% is standard for cell culture assays to eliminate confounding variables. Typical order sizes range from 5 mg to 100 mg.
Bulk Wholesale: Distributors supply MOT C peptide in bulk quantities (1 g to 100 g) to cosmetic manufacturers. Packaging is typically in vacuum-sealed vials or foil pouches with desiccants to maintain stability during transit. Custom purity specifications and third-party testing reports are often negotiated.
| Item | Our Product (High-Purity MOT C) | Alternatives (Low-Grade Peptides) | Advantages |
|---|---|---|---|
| Purity Level | ≥98% by HPLC | 70-90% by HPLC | Reduces batch failures and immunogenicity |
| Endotoxin Content | <1 EU/mg | 5-20 EU/mg | Safe for cosmetic and lab use |
| Solubility | ≥10 mg/mL in water | <5 mg/mL, often requires organic solvents | Easier formulation in aqueous systems |
| Stability | 24 months at -20°C | 6-12 months at -20°C | Longer shelf life reduces waste |
| Heavy Metals | Meets USP <232> limits | May exceed limits for lead or arsenic | Complies with cosmetic regulations |
| Batch Consistency | CV <5% across batches | CV >15% across batches | Reliable formulation performance |
When sourcing MOT C peptide in bulk, buyers must navigate common pitfalls to ensure they receive material that meets their specifications. The following checklist addresses key selection standards:
Common pitfalls include accepting peptides with purity below 95% for cosmetic use, which can lead to formulation instability, discoloration, or reduced efficacy. Additionally, some suppliers may substitute MOT C peptide with similar sequences that lack mitochondrial-targeting properties, so mass spectrometry confirmation is essential.
High-purity MOT C peptide offers several distinct advantages for B2B buyers in the cosmetic and lab raw material markets:
Purity and Consistency: With ≥98% purity and batch-to-batch coefficient of variation below 5%, formulators can rely on consistent bioactivity and formulation performance. This reduces the need for re-formulation or batch adjustments.
Stability: Lyophilized powder stored at -20°C remains stable for up to 24 months, minimizing inventory risk. Reconstituted solutions maintain integrity for 7 days under refrigeration, allowing for flexible production schedules.
Cost Performance: While high-purity peptides command a premium, the reduced failure rate and longer shelf life lower the total cost of ownership. Bulk pricing for 1 g quantities typically ranges from $50 to $150 per gram, depending on purity and certification requirements.
Technical Support: Reputable suppliers provide formulation guidance, solubility optimization, and custom packaging options. This support is invaluable for companies new to peptide-based cosmetics or those scaling up production.
Q: What is the minimum purity required for MOT C peptide in cosmetic formulations?
A: For cosmetic formulations, a minimum purity of 98% by HPLC is recommended. Lower purity levels may introduce impurities that cause discoloration, precipitation, or reduced bioactivity. Premium formulations often specify ≥99% purity for optimal results.
Q: How should MOT C peptide be stored to maintain stability during bulk sourcing?
A: Lyophilized MOT C peptide should be stored at -20°C in a dry, light-protected environment. For bulk quantities, vacuum-sealed packaging with desiccants is recommended. Avoid repeated freeze-thaw cycles by aliquoting into single-use vials. Reconstituted solutions should be used within 7 days when stored at 2-8°C.
Q: Can MOT C peptide be used in water-based cosmetic formulations without stabilizers?
A: Yes, high-purity MOT C peptide is soluble in water at concentrations up to 10 mg/mL without additional stabilizers. However, for long-term stability in finished products, formulators often include antioxidants like vitamin E or chelating agents like EDTA to prevent oxidation. Always conduct compatibility testing with your specific formulation base.
Abstract: The Mot C Peptide market is poised for significant growth through 2026, driven by its unique amino acid composition and therapeutic applications. Research data highlights expanding demand in metabolic disorder treatments. Industry trends indicate rising R&D investments and product innovations. A comparative analysis reveals variations in purity, stability, and delivery systems among key suppliers. This guide provides actionable insights for product selection, emphasizing quality benchmarks and regulatory compliance. Essential industry knowledge includes synthesis methods and clinical efficacy, aiding stakeholders in navigating this evolving landscape.
Target Keyword: mot c peptide
The Mot C Peptide, a synthetic oligopeptide characterized by a specific sequence of amino acids, has garnered significant attention within the B2B cosmetic and laboratory raw material sectors. Its molecular structure is engineered for targeted interaction with cellular pathways, distinguishing it from standard peptide chains. For procurement specialists and formulation scientists, understanding the precise technical parameters is the first step in evaluating its commercial viability. The peptide is typically supplied as a lyophilized powder, requiring specific handling to maintain its bioactivity.
Industry data from a 2025 market analysis indicates that the demand for high-purity Mot C Peptide (≥98%) has grown by 34% year-over-year, driven by its application in advanced metabolic disorder research and high-end cosmetic formulations. Suppliers failing to meet this purity benchmark are increasingly excluded from premium supply chains.
The production of Mot C Peptide involves solid-phase peptide synthesis (SPPS), a method that allows for precise control over the amino acid chain assembly. This process is followed by rigorous purification and quality control steps to ensure batch-to-batch consistency. For B2B buyers, the manufacturer's adherence to these protocols is a direct indicator of product reliability. A robust quality management system is non-negotiable for regulatory compliance in both cosmetic and lab research applications.
The versatility of Mot C Peptide allows it to be integrated into several commercial channels. Its primary demand stems from the cosmetic formulation industry and advanced laboratory research. For bulk wholesale buyers, understanding these application scenarios helps in forecasting demand and selecting the appropriate grade. The peptide's stability and purity directly influence its performance in these diverse environments.
When sourcing peptides for commercial use, the distinction between high-grade Mot C Peptide and ordinary low-grade alternatives is critical. The following comparison highlights key differentiators that impact product performance and regulatory acceptance. B2B buyers must prioritize these factors to avoid costly formulation failures or compliance issues.
| Item | Our Product (High-Grade) | Alternatives (Low-Grade) | Advantages |
|---|---|---|---|
| Purity (HPLC) | ≥98% | ≤90% | Higher purity reduces side reactions and ensures consistent bioactivity. |
| Stability | Stable for 24 months at -20°C | Degrades within 6 months | Longer shelf life reduces inventory risk and waste. |
| Endotoxin Level | <1 EU/mg | >10 EU/mg | Low endotoxin is essential for cell-based research and sensitive formulations. |
| Documentation | Full CoA, MSDS, and stability data | Basic CoA or no documentation | Complete documentation supports regulatory filing and quality audits. |
Navigating the Mot C Peptide market requires a strategic approach to avoid common pitfalls. B2B buyers often face challenges related to purity inconsistencies, inadequate documentation, and unreliable supply chains. This guide provides a checklist for evaluating potential suppliers and ensuring a successful procurement process. Prioritizing quality benchmarks over price alone is a key takeaway for industry stakeholders.
The primary advantages of sourcing premium Mot C Peptide are rooted in its technical specifications and the supplier's commitment to quality. For B2B clients, these advantages translate directly into operational efficiency and product excellence. The following points summarize the key benefits that distinguish a reliable supply partner.
Q: What is the recommended storage condition for reconstituted Mot C Peptide?
A: After reconstitution in sterile water or PBS, the solution should be stored at 2-8°C and used within 7-14 days. For longer storage, aliquot and freeze at -20°C, avoiding repeated freeze-thaw cycles to maintain stability.
Q: How can I verify the purity of a Mot C Peptide batch before purchase?
A: Request a Certificate of Analysis (CoA) from the supplier that includes the HPLC chromatogram and purity percentage. For critical applications, consider sending a sample to an independent third-party laboratory for verification.
Q: Is Mot C Peptide suitable for use in cosmetic formulations intended for international markets?
A: Yes, provided the supplier provides full documentation, including a Certificate of Analysis, Material Safety Data Sheet, and evidence of compliance with relevant regulations (e.g., EU Cosmetics Regulation, FDA guidelines). High purity and low endotoxin levels are essential for market acceptance.